All In Biotech

Drug Trial Radar · NCT05037409

Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants

A PHASE 1, RANDOMIZED, DOUBLE BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETICS FOLLOWING SINGLE INTRAVENOUS DOSE OF PF-06823859 IN JAPANESE HEALTHY PARTICIPANTS

Last checked: Nov 20, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

13

Actual

Start

Sep 28, 2021

Primary completion

Mar 27, 2022

Study completion Mar 27, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Purpose of the study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics (PK) of PF-06823859 following a single intravenous dose of PF-06823859 300 and 900 mg in Japanese healthy adult participants.

Conditions

  • Healthy

Interventions

  • PF-06823859Drug

    low dose or high dose intravenous infusion

  • PlaceboDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to maximum of Day 157
  2. Number of Participants With Infusion Related Reaction (IRR)Time frame: Day 1 up to maximum of Day 157
  3. Number of Participants With Infusion Site ReactionTime frame: From start of study intervention infusion up to 60 minutes on Day 1
  4. Number of Participants With Viral InfectionTime frame: Day 1 up to maximum of Day 157
  5. Number of Participants With Laboratory Test AbnormalitiesTime frame: Day 1 up to maximum of Day 157
  6. Number of Participants With Vital Sign Abnormalities of Pre-defined CriteriaTime frame: From baseline (pre-dose measurement at Day 1) up to Day 157
  7. Number of Participants With Electrocardiogram (ECG) Abnormalities of Pre-defined CriteriaTime frame: From baseline (pre-dose measurement at Day 1) up to Day 157

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical Corporation Shinanokai Shinanozaka Clinic

    Shinjuku-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.